Payment overview · 2025
General Payments
$930.87
50 reported records · 16 companies
Healthcare provider profile · identity verified
Timothy Daugherty, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAVANNAH, GA · NPI 1821031840
Verified facts
What the public records show
CMS Open Payments records show Timothy Daugherty, MD received $930.87 in general payments during 2025 across 50 reported records.
Amgen Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $176.52 | 19.0% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $170.83 | 18.4% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $131.38 | 14.1% | 6 | 2025 |
| AXOGEN | Unresolved — no canonical attribution shown | $79.64 | 8.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.88 | 7.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.29 | 5.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.59 | 3.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.54 | 3.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.20 | 3.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.77 | 3.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.80 | 2.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.60 | 2.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.41 | 2.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.96 | 2.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.00 | 2.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.46 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $930.87 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $127.99 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $127.99 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $112.12 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $109.01 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.82 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.53 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.90 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 19 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 22 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 240 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
240 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
74 | 73 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1336 | 419 |
| Levothyroxine Sodium | Levothyroxine Sodium | 893 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 701 | 222 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 610 | 205 |
| Pantoprazole Sodium | Pantoprazole Sodium | 544 | 183 |
| Losartan Potassium | Losartan Potassium | 382 | 121 |
| Omeprazole | Omeprazole | 358 | 114 |
| Hydrochlorothiazide | Hydrochlorothiazide | 306 | 102 |
| Ezetimibe | Ezetimibe | 297 | 91 |
| Trazodone Hcl | Trazodone Hcl | 262 | 99 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 254 | 80 |
| Gabapentin | Gabapentin | 253 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 78 |
| Meloxicam | Meloxicam | 250 | 93 |
| Simvastatin | Simvastatin | 250 | 80 |
| Metformin Hcl Er | Metformin Hcl | 240 | 81 |
| Ozempic | Semaglutide | 240 | 61 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 234 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 81 |
| Prednisone | Prednisone | 228 | 177 |
| Duloxetine Hcl | Duloxetine Hcl | 215 | 68 |
| Alendronate Sodium | Alendronate Sodium | 207 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 189 | 66 |
| Potassium Chloride | Potassium Chloride | 178 | 71 |
| Famotidine | Famotidine | 169 | 53 |
| Eliquis | Apixaban | 155 | 38 |
| Furosemide | Furosemide | 148 | 63 |
| Carvedilol | Carvedilol | 145 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 140 | 43 |
| Allopurinol | Allopurinol | 139 | 48 |
| Lisinopril | Lisinopril | 133 | 44 |
| Montelukast Sodium | Montelukast Sodium | 130 | 37 |
| Fenofibrate | Fenofibrate | 124 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 38 |
| Farxiga | Dapagliflozin Propanediol | 116 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 33 |
| Metformin Hcl | Metformin Hcl | 112 | 42 |
| Valsartan | Valsartan | 110 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 35 |
| Celecoxib | Celecoxib | 96 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 40 |
| Bupropion Xl | Bupropion Hcl | 82 | 25 |
| Buspirone Hcl | Buspirone Hcl | 82 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Mirtazapine | Mirtazapine | 79 | 31 |
| Sertraline Hcl | Sertraline Hcl | 79 | 31 |
| Propranolol Hcl Er | Propranolol Hcl | 77 | 26 |
| Donepezil Hcl | Donepezil Hcl | 76 | 28 |
| Spironolactone | Spironolactone | 75 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 74 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 36 |
| Gemtesa | Vibegron | 71 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 18 |
| Azithromycin | Azithromycin | 64 | 58 |
| Tramadol Hcl | Tramadol Hcl | 64 | 24 |
| Alprazolam | Alprazolam | 63 | 26 |
| Jardiance | Empagliflozin | 63 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | 20 |
| Memantine Hcl | Memantine Hcl | 56 | 22 |
| Finasteride | Finasteride | 55 | 16 |
| Glimepiride | Glimepiride | 55 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 15 |
| Vascepa | Icosapent Ethyl | 54 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 17 |
| Levofloxacin | Levofloxacin | 53 | 50 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 34 |
| Synthroid | Levothyroxine Sodium | 48 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 39 |
| Ondansetron Odt | Ondansetron | 44 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 18 |
| Atenolol | Atenolol | 43 | 13 |
| Mounjaro | Tirzepatide | 43 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 39 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 23 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Linzess | Linaclotide | 30 | 11 |
| Topiramate | Topiramate | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Klor-Con M10 | Potassium Chloride | 28 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 12 |
| Azelastine Hcl | Azelastine Hcl | 27 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 19 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 11 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Minoxidil | Minoxidil | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 20 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Toprol Xl | Metoprolol Succinate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $930.87 · 50 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FANAPT, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, INSPIRE, Korlym, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error